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Intra-articular injections of platelet-rich plasma releasate reduce pain and
synovial inflammation in a mouse model of osteoarthritis
ABSTRACT 
Background
Osteoarthritis (OA) is a degenerative joint disease leading to pain and disability for which no
curative treatment  currently exists.  A promising biological  treatment  for OA is intra-articular
administration  of  platelet  rich  plasma  (PRP).  PRP injections  in  OA joints  can  relieve  pain,
although the exact working mechanism is unclear. 
Purpose
To examine the effects of PRP on pain, cartilage damage and synovial inflammation in a mouse
OA model. 
Study design
Controlled laboratory study.
Methods 
OA was induced unilaterally in the knees of male mice (n=36) by two intra-articular injections of
collagenase at days -7 and -5. At day 0, pain was measured by registering weight distribution on
the hind limbs; after which mice were randomly divided in two groups. Mice received three intra-
articular injections of PRP-releasate (PRPr) or saline in the affected knee. Seven mice per group
were euthanized at day 5 to assess early synovial inflammation and cartilage damage. Pain in the
remaining mice was registered for a total of three weeks. These mice were euthanized at day 21
to assess cartilage damage and synovial inflammation on histology. Antibodies against iNOS,
CD163 and CD206 were used to  identify  different  subtypes  of  macrophages  in  the  synovial
membrane.
Results 
Mice  in  the  PRPr  group  increased  the  distribution  of  weight  on  the  affected  joint  in  two
consecutive weeks after start of the treatment (P<0.05), whereas mice in the saline group did not.
At day 21, PRPr injected knees had a thinner synovial membrane (P<0.05), and a trend towards
less cartilage damage in the lateral joint compartment (P=0.053) than saline injected knees. OA
knees treated with saline showed less anti-inflammatory (CD206+ and CD163+) cells at day 5
than healthy knees, an observation which was not made in the PRPr-treated group. A higher level
of pain at day 7 was associated with a thicker synovial membrane at day 21. The presence of
CD206+ cells was negatively associated with synovial membrane thickness
Conclusions 
In a murine OA model, multiple PRPr injections reduced pain and synovial thickness, possibly
through modulation of macrophage subtypes. 
Clinical relevance
PRPr injections shortly after joint trauma can reduce pain and, synovial inflammation and may
inhibit OA development in patients. 
What is known about the subject?
Platelet rich plasma (PRP) is a biological treatment used in human clinical trials for various 
musculoskeletal diseases, including osteoarthritis (OA). Multiple PRP injections were shown to 
have beneficial effects on pain and functional impairment, but no effect was found on the severity
of radiographic OA. Anti-inflammatory effects of PRP have been demonstrated in vitro on 
osteoarthritic cartilage and synovium
What this study adds to existing knowledge.
Here we demonstrate that multiple PRPr injections in a OA model reduce pain and synovial 
membrane thickness. We provide indications for an effect of PRPr on modulation of synovial 
macrophage phenotype. This indicates an anti-inflammatory working mechanism of  PRPr in 
vivo. 
INTRODUCTION
 Osteoarthritis  (OA) is  a degenerative joint  disease,  characterized  by loss of cartilage
integrity,  changes  in  subchondral  bone,  formation  of  osteophytes  and  inflammation  of  the
synovial membrane. This process results in pain and disability. Current treatments focus on pain
reduction, exercise therapy and – in end-stage OA – joint replacement. To this day no curative
treatment exists for OA. Since joint arthroplasties have a limited life-span, the need for disease-
modifying drugs or therapies is high. Ideally such a therapy would inhibit or repair damage to the
joint  tissues  and  reduce  pain  and  disability.  A  biological  therapy  for  tissue  injury  that  has
emerged in recent years is treatment with platelet-rich plasma (PRP). PRP is a plasma product
extracted from whole blood that contains at least 1.0 x 106 platelets per microliter.29 The platelets
undergo  degranulation  after  which  they  release  growth  factors  and  cytokines  such  as
transforming growth factor beta (TGFβ) and platelet-derived growth factor (PDGF),β) and platelet-derived growth factor (PDGF),) and platelet-derived growth factor (PDGFβ) and platelet-derived growth factor (PDGF),),24,  29,  37 two
important factors in tissue healing. PRP can be activated prior to use resulting in PRP-releasate
(PRPr),  a  product  containing  low amounts  of  leucocytes  and  high  concentrations  of  growth
factors.9 Our group and others  have  used  PRPr  previously  and have  shown that  it  has  anti-
inflammatory  and positive  effects  on  matrix  synthesis  and accumulation.  Fβ) and platelet-derived growth factor (PDGF),urthermore  it  can
induce the chondrogenic properties of chondrocytes.20, 47, 52 PRPr  has been used in a rabbit model
and  clinically  to  successfully  induce  the  reparative  effect  of  degenerated  intervertebral  disc
degeneration.1, 38
Several clinical trials in OA have concluded that multiple PRP injections are safe and
have a beneficial effect on OA symptoms such as pain, for up to 12 months.6, 17, 26, 33, 34, 45 Evidence
is accumulating from both in vitro and in vivo studies for PRP's potential in the treatment of OA.
Fβ) and platelet-derived growth factor (PDGF),rom preclinical research we know that  PRP promotes the proliferation of cells derived from
human synovium and cartilage,39, 42 and that PRP-treated chondrocytes repair cartilage better than
non-treated  chondrocytes.58 These cells  in  turn produce more superficial  zone protein  (SZP),
which functions as a boundary lubricant that helps to reduce friction and wear.42, 43, 48 PRP itself
was also shown to reduce friction in bovine articular cartilage explants.42 The anti-inflammatory
effects of PRP have been demonstrated both in a co-culture system of osteoarthritic cartilage and
synovium42 and  in  human  osteoarthritic  chondrocytes,  where  it  reduced  multiple  pro-
inflammatory  effects  induced by IL-1.52 Fβ) and platelet-derived growth factor (PDGF),urthermore,  in  a canine  OA model,  multiple  PRP
injections were shown to have beneficial effects on pain and functional impairment, but no effect
on the severity of radiographic OA.11 
However, while the use of PRP products seems promising for the treatment of OA, the
wide  variability  in  outcome  parameters  evaluated,  in  models  used  and  in  PRP  and  PRPr
production  protocols  makes  interpretation  of  results  between  studies  difficult.13,  22,25 This
difficultly in comparing the results of PRP research may be one of the reasons why the exact
working  mechanisms  of  intra-articular  injected  PRP  products  are  not  fully  understood.
Unravelling this mechanism could provide an opportunity to further improve therapeutic PRP
efficacy. 
In this study we assessed the effect of human PRPr compared to saline in a murine model
of  collagenase-induced  OA (CIOA).  We  studied  the  effects  of  PRPr  on  several  OA related
processes  in  the  joint:  pain,  cartilage  damage  and  synovial  inflammation  and  evaluated
correlations  between  these  parameters.  We  payed  particular  attention  to  effects  on  different
macrophage phenotypes in the synovium. Our hypothesis is that multiple intra-articular injections
of PRPr will reduce pain, have a protective effect on cartilage and inhibit synovial inflammation.
Materials Methods
Platelet rich plasma releasate preparation
Human PRP was acquired from the national blood bank (Sanquin, Amsterdam, The Netherlands)
with a platelet count of 8.5 x 108 /ml. This PRP product is produced by pooling buffy coats of 5
different donors in plasma. After centrifugation, the platelets are filtered out to produce the PRP.
The blood samples had identical ABO and Rh(D) compatible blood type, and were pathogen free.
PRP was activated by adding 10% v/v 228 mM CaCl2  and incubated on a rotating device at
37°C.52 After one hour of incubation a clot was formed and the supernatant was harvested. This
supernatant contains the released factors of the activated platelets and hence is called the PRP
releasate  (PRPr).  Whereas  erythrocytes  could  be  detected  in  the  PRP,  they  were  no  longer
detected  after  the  activation  of  the  PRP  by  a  clinical  cytometer  (Model  xn1000,  Sysmex
Netherlands BV, Etten-Leur,  Netherlands). Leukocytes were not detectable in the PRP or the
PRPr. After harvesting the PRPr the samples were stored at -80°C and used within a week for in
vivo experiments. The concentration of PDGFβ) and platelet-derived growth factor (PDGF),-BB in the cryopreserved samples was 1.2 x 104 pg/
ml, measured by ELISA, confirming that released products were present in the supernatant.
Animal model of injury and treatment
All animal experiments were performed on 36 male C57/Bl6 mice age 12 weeks (blinded), with
approval of the animal ethical committee (blinded 116-14-03). The mice were housed in groups
of three or four mice per cage, under 12 hours light-dark cycle at a temperature of 24°C degrees
Celsius,  and  had  access  to  water  and  food  ad  libitum  at  the  animal  testing  facilities.  
Before starting the experiments, mice were allowed to acclimatize for a week. In all mice, OA
was induced unilaterally by two intra-articular injections of 6 µl of 3 units collagenase type VII
(Sigma-Aldrich) at days -7 and -5. Collagenase induced OA is an established model for joint
instability in mice.27,  44,  49,  54,  55 All intra-articular injections were applied under 2.5% isoflurane
anesthesia,  with a 50 µL glass syringe (Hamilton Company, Ghiroda,  Romania) using a 30G
needle (Becton, Dickinson and Company, New Jersey,  USA). The contralateral  control knees
were kept naïve and were not injected with any substance. Mice were randomly assigned to either
the treatment group with 6 µl PRPr (n=11 mice) or the control group (n=11 mice) with 6 µl
saline. Both groups received three consecutive PRPr or saline injections; the first injection was
given  7  days  after  the  first  collagenase  injection  (referred  to  as  day  0)  and  repeated  with
consecutive injections at day 2 and 4 (Fβ) and platelet-derived growth factor (PDGF),igure 1). Weight distribution over the left and right hind
limbs was evaluated as an indicator of pain at day 0 and hereafter once weekly for 3 weeks.  
During the whole experiment the animals were capable to move around freely and reach the food
pellets and drink nozzle on the top of their cage.  Animals were euthanized at day 21 and knee
joints were harvested for histological analysis. 
To assess the early effects of PRPr on synovial inflammation, an additional group of animals was
used containing  7 mice in each group. These animals  underwent identical  OA induction and
treatment protocols. They were euthanized at day 5 after the start of PRPr treatment and knee
joints were prepared for histological evaluation.
Measurement of hind limb weight distribution
Hind  limb  weight  distribution  was  registered  with  an  incapacitance  tester53 (Linton
Instrumentation,  Norfolk,  UK) as an indicator  of pain. It is a static method to measure pain,
which is validated in mouse, rats and other animal models.3, 11, 14, 15, 19, 53 Mice were positioned on
the incapacitance meter with each hind limb resting on a separate force plate. Measurements were
performed at day 0, just before therapy administration and hereafter at day 7, 14 and 21.The
observer  was  blinded  to  the  pressures  measured  during  the  test.  Therefore  afterwards,
measurements with a registration of below 3 grams (<10% of total bodyweight) per hind limb or
less than 10 grams (<30% of total bodyweight) in total over both hind limbs were excluded. On
average 15 measurements  per time point per animal  were available.  Fβ) and platelet-derived growth factor (PDGF),or each time point  per
mouse, the average of these measurements was used to calculate the percentage of weight on the
affected limb as an indication of pain in the affected limb. A single value per measurement time
point was used for statistical analyses.
Histological analyses
Knees were fixed in formalin 4% (v/v) for one week, decalcified in 10% EDTA for 2 weeks and
embedded in paraffin. Coronal sections of 6 µm were cut for analysis of synovial inflammation
and cartilage damage. 
Structural integrity
Cartilage  damage was evaluated  on thionin-stained sections  by two observers  blinded to  the
treatment groups with a scoring system described by Glasson et al.16 Briefly this score ranges
from 0 for normal cartilage, to 6 for cartilage with clefts and erosion to the calcified cartilage in
>75%  of  articular  surface.  Fβ) and platelet-derived growth factor (PDGF),or  each  knee  the  cartilage  quality  in  the  lateral  and  medial
compartment of the knee was scored on 3 sections with 180 µm interval between the sections.
The maximum and sum score of the 3 sections, for each compartment was taken for analyses.16
Data from the lateral compartment is shown, since we used a mild OA model and this was the
area where most damage was observed. Thionin stain was used instead of Safranin O because of
previously described limitations of the latter, especially regarding sensitivity of GAG depletion.5,
7 As an internal check, all knees of the animals terminated at the early time point were stained and
scored using both Thionin and Safranin O stain, which showed a very high accordance between
both methods (data not shown).  
Synovial inflammation
Fβ) and platelet-derived growth factor (PDGF),or synovial  inflammation assessment,  sections were stained with hematoxylin eosin.  Images
were  acquired  using  the  NanoZoomer  Digital  Pathology  program  (Hamamatsu  Photonics,
Ammersee, Germany). Synovial thickness was measured from the capsule to the superficial layer
of the synovial membrane in the parapatellar recesses at the medial and the lateral side at three
positions per section, based on a previously described method.49 These measurements were done
on three sections per knee, with 180 µm between the sections. In total we obtained 18 synovium
thickness measurements per knee, which were averaged to obtain a single value per knee joint. 
Macrophage staining
To evaluate the macrophage subtypes in the synovial membrane, inducible nitric oxide (iNOS)
was used as a marker for pro-inflammatory macrophages, cluster of differentiation 163 (CD163)
as  a  marker  for  anti-inflammatory  macrophages,  and  CD206  as  a  marker  for  tissue  repair
macrophages. Fβ) and platelet-derived growth factor (PDGF),or this purpose, sections were deparaffinized, washed and heat-mediated antigen
retrieval was performed for CD163 and CD206, by placing the slides in 95°C citrate buffer (pH
6) for 20 minutes. Antigen retrieval for iNOS was performed in by placing the slides in 95°C
Tris-EDTA buffer (pH 9) for 20 minutes. Blocking of aspecific binding was done with 10% goat
serum (Southern Biotech, Birmingham, USA) for 30 minutes. Hereafter, sections were incubated
with the primary antibodies iNOS (2.0 µg/ml #15323, Abcam, Cambridge, UK), CD163 (0.34
µg/ml, #182422, Abcam, Cambridge, UK), and CD206 (2.5 µg/ml,#64693, Abcam, Cambridge,
UK)  for  1  hour,  followed  by  30  minutes  incubation  with  a  biotinylated  anti-rabbit  Ig  link
(Biogenex, HK-326-UR, Fβ) and platelet-derived growth factor (PDGF),remont, USA), diluted 1:50 in PBS/1%BSA. Thereafter, sections were
incubated with an alkaline phosphatase-conjugated streptavidin (Biogenex, HK-321-UK) label
diluted 1:50 in PBS/1%BSA. To reduce background, endogenous alkine phosphatase activity was
inhibited  with  levamisole  (Sigma-Aldrich  Chemie  N.V.  Zwijndrecht,  The  Netherlands).  Neu
Fβ) and platelet-derived growth factor (PDGF),uchsin  (Fβ) and platelet-derived growth factor (PDGF),isher  Scientific,  Vienna,  Austria)  and  Napthol  AS-MX phosphate  (Sigma-Aldrich
Chemie  N.V.  Zwijndrecht,  The  Netherlands)  substrate  was  used  for  color  development  and
counterstained with hematoxylin. As a negative control Rabbit IgG antibody (Dako Cytomation,
Glostrup, Denmark) was used. The sections were ranked from weakest to strongest staining for
either iNOS, CD163, or CD206, by two observers blinded for the treatment group. The maximum
rank was based on the total number of joints scored for the individual staining. When multiple
sections had similar strength of staining, the mean of the rank numbers was given to each section.
Per section the mean rank of both observers was used for analyses.
Statistical Analysis  
Fβ) and platelet-derived growth factor (PDGF),or the late time point and pain reduction we consider a decrease in pain of 20% in the therapy
groups to be relevant in our study. According to a power calculation (using a standard deviation
of 15%), with a statistical power level (1-β) and platelet-derived growth factor (PDGF),) of 0.8 and significance level (α) of 0.05, our sample) of 0.05, our sample
size per group for a two tailed hypothesis test was 9 mice. Fβ) and platelet-derived growth factor (PDGF),or the short term we considered a
25% decrease of synovial thickness as relevant for our study. According to a power calculation of
the sample size (using a standard deviation of 30%), with a statistical power level (1-β) and platelet-derived growth factor (PDGF),) of 0.8 and
significance level (α) of 0.05, our sample) of 0.05, our sample size per group for a two tailed hypothesis test was 5
mice. Two additional mice per group gave us n=11 for late time point and n=7 mice for the early
time point. This lead to a total of n=18 mice per treatment group and 36 mice in total. 
Data was analyzed with IBM SPSS statistics 21  (SPSS, Chicago, IL). Fβ) and platelet-derived growth factor (PDGF),or the effect on weight
distribution, normality was confirmed with a Shapiro Wilk test. Two-tailed paired t-tests were
conducted to evaluate differences between time points within each group and two tailed unpaired
t-tests  were  conducted  to  evaluate  differences  between  treatment  groups  at  each  time  point.
Statistic testing on synovial thickness measurements where conducted using a Welch t-test, after
normality  was confirmed  with  a  Shapiro-Wilk  test  for  knees  at  both  day 5  and day 21.  To
compare the maximum OA scores between saline and PRPr treated groups, a Mann-Whitney U
test  was  performed.  A  Kruskal-Wallis  test  was  performed  for  the  ranked  macrophage  data
between the healthy control, saline and PRPr group. Fβ) and platelet-derived growth factor (PDGF),or all tests, P values < 0.05 were considered
statistically significant. 
Correlation analysis was performed by means of a Spearman’s rho test. All data collected were
categorized  per  animal.  In  this  way  we  were  able  to  make  correlations  between  pain
measurements at different time points and the corresponding histological findings at day 21. Fβ) and platelet-derived growth factor (PDGF),or
the interpretation  of  the correlation  coefficient  we used the  absolute  value of rs,  dividing the
correlations in weak (<0.5), moderate (0.40-0.59), strong (0.60-0.79) and very strong (>0.80).
Correlations were significant if P values < 0.05. 
Results
Multiple PRPr injections reduce pain
We determined the weight distribution over the hind limbs as an indicator of pain (Fβ) and platelet-derived growth factor (PDGF),igure 2A).
Seven days after induction of OA, 43.1 ± 9.6% of weight was distributed on the affected limb,
indicating pain (Fβ) and platelet-derived growth factor (PDGF),igure 2B). Mice in the PRPr group significantly increased the weight on the
affected joint on day 7 (P=0.041) and 14 (P=0.034) compared to day 0, indicating a reduction in
pain. The mice that received saline injections did not significantly change the weight distribution
on any of the time points, compared to the start of treatment, albeit a trend for improvement over
time was visible. The largest difference between PRPr and saline treated animals was seen at day
7, although this did not reach statistical significance.  
Multiple PRPr injections have no effect on cartilage damage
Collagenase  injected  knees  that  were  treated  with  saline  (control  group)  had  more  cartilage
damage than the healthy controls at day 21 for maximum OA scores and at both time points for
sum scores, confirming development of OA (Fβ) and platelet-derived growth factor (PDGF),igure 3A, B, P<0.05). PRPr injected knees were
not significantly different from the healthy group at both time points regarding maximum OA
scores. Regarding sum scores, this was only seen at the later time point. This could suggest a
protective  effect  of  the  PRPr  on  cartilage,  although  direct  comparison  of  cartilage  damage
between saline and PRPr groups at day 21 showed only a trend towards a protective effect of
PRPr (P=0.053). 
Fβ) and platelet-derived growth factor (PDGF),ig 3 revised, graph B added
Supp file 1: A-B = healthy (same plaatje als in fig 3, C = Saline, D = PRPr)
Multiple PRPr injections reduce synovial membrane thickening
Collagenase injected knees displayed a significantly thickened synovial membrane compared to
healthy knees. Although the synovial membrane thickness was not statistically different between
PRPr and saline injected groups 5 days after start of treatment, synovial membrane thickness at
day 21 was significantly less in the PRPr group than in the saline control group (Fβ) and platelet-derived growth factor (PDGF),igure 4A,
P=0.041). Overall, synovial membrane thickness was largely reduced over time between day 21
and day 5 (P<0.001).
Multiple PRPr injections maintain the CD206 and CD163 positive macrophages
To further  analyze  the  synovial  inflammation  process,  we assessed  the  presence  of  different
macrophage  subtypes.  We  examined  the  presence  of  iNOS,  CD206  and  CD163  positive
macrophages  by ranking healthy,  collagenase  injected  saline control  and collagenase injected
PRPr treated knees at day 5 and day 21 between weak, moderate and strong staining intensity
(Fβ) and platelet-derived growth factor (PDGF),igure 5A1-C4). The presence of iNOS positive macrophages, indicating a pro-inflammatory
response, was higher in collagenase injected knees than in healthy control knees at both day 5
(saline P=0.004; PRPr P=0.006) and day 21 (saline P=0.016; PRPr P=0.046), independent  of
treatment  (Fβ) and platelet-derived growth factor (PDGF),igure 5A).  Although no significant  differences  were observed in the presence  of
iNOS positive macrophages between treatment groups,  PRPr injected knees did show a trend
towards less iNOS positive macrophages than in the saline injected knees at day 5 (P = 0.109).
We furthermore determined the presence of macrophages related to tissue repair (CD206+) and
anti-inflammatory macrophages (CD163+). In the collagenase injected saline control group, the
presence of CD163 and CD206 positive macrophages was significantly lower than in the healthy
knees, at day 5 (Fβ) and platelet-derived growth factor (PDGF),igure 5B-C, P=0.024 and P=0.042 respectively). The presence of CD206 and
CD163 positive macrophages in the PRPr treated knees did not differ from that of saline treated
knees, at day 5 or day 21).  In the saline group at day 21, the presence of CD206, but not CD163,
was significantly increased compared to day 5 (P=0.023 and P=0.185 respectively). 
Fβ) and platelet-derived growth factor (PDGF),ig 5 revised, all histology added 
Pain reduction is associated with a thinner synovial membrane
Interestingly, reduction of pain measured at day 7 was strongly associated with a thinner synovial
membrane  at  day  21 within  the  same animals  (Table  1,  P=0.002).  There  was  no  significant
correlation between pain reduction at day 21 and synovial thickness at day 21, possibly due to the
overall pain reduction seen in all animals. Fβ) and platelet-derived growth factor (PDGF),urthermore, the presence of iNOS+ macrophages was
moderately associated with lateral OA damage (P=0.02). No significant associations were found
between iNOS+ macrophages  and pain  or  synovial  thickness  between treatment  groups.  The
presence of repair  macrophages  (CD206+) was associated  with a thinner  synovial  membrane
(P=0.007) and anti-inflammatory macrophages (CD163+, P<0.001).
Discussion
The  results  of  this  study  suggest  that  multiple  intra-articular  injections  of  PRPr  in  a
collagenase induced OA (CIOA) mouse model reduce synovial inflammation and might have a
protective effect on cartilage, while at the same time reducing pain. The strongest effect on pain
reduction was seen in the period shortly after start of treatment. Next to pain reduction, multiple
PRPr  injections  inhibited  synovial  inflammation,  as  demonstrated  by  a  thinner  synovial
membrane compared to the saline control.  Fβ) and platelet-derived growth factor (PDGF),urthermore,  PRPr injections had an effect on the
balance between inflammatory and anti-inflammatory macrophages in the synovial membrane, in
particular  by  preventing  the  early  decrease  in  anti-inflammatory  macrophages  seen  after
induction  of  CIOA. We also  noted  that,  although  the  association  was  not  significant,  PRPr-
injected knees tended to have fewer pro-inflammatory iNOS+ macrophages than saline-injected
knees.
 Collagenase  injections  induce joint  inflammation,  in particular  in the first  two weeks,
making this model suitable for testing potential anti-inflammatory therapies. Fβ) and platelet-derived growth factor (PDGF),or example, others
have  shown  that  intra-articular  injection  of  adipose-derived  stem cells  (ASC)  in  this  model
reduces synovial inflammation at day 42, when ASCs are injected one week after induction of
CIOA.49 This  demonstrates  the  possibility  to  interfere  with  inflammation  using  biological
treatments  in  this  model.  Our results  confirm that  early  intervention  in  this  model  can  have
beneficial effects. 
PRPr injections reduced pain for two consecutive weeks. Mice with high pain levels at
day 7 were very likely to have thicker synovial membranes two weeks later. The pathway by
which PRPr reduces pain may involve inhibition of the production of prostaglandin E2 (PGE2).
PGE2 is a lipid mediator of inflammatory pain that causes pain hypersensitivity via nociceptor
sensitization.51 In  an  inflammatory  environment,  the  main  contributors  to  PGE2  release  are
thought to be tissue-resident macrophages.51 Our data suggest that PRPr-injected knees may have
fewer pro-inflammatory and more anti-inflammatory macrophages, possible resulting in lower
PGE2 production. It is known that PRP can promote the differentiation of monocytes towards
repair and anti-inflammatory CD206 and CD163-positive macrophages.40 This is supported by
the finding in a rabbit knee osteoarthritis model that intra-articular injections of leucocyte-poor
PRP reduced PGE2 concentrations.57  Moreover, PRPr has been reported to contain high levels of
interleukin 1 receptor antagonist (IL-1Ra)35  that can inhibit acute inflammation caused by IL1
and promote macrophage polarization towards an M2 phenotype.28 Our finding that animals in
neither the treated nor the untreated group appeared to experience any pain at three weeks may be
partly due to the fact that acute inflammation weakens in time after collagenase injection, thereby
reducing nociceptive input to the central nervous system. Less nociceptive input can be preceded
by desensitization of the mice nervous system for pain. In the latter case, the threshold for the
activation of the joint nociceptors is reduced, and thus a bigger stimulus is needed to register
pain.31 
Besides synovial inflammation, cartilage damage is an important hallmark of OA. In this
study,  28  days  after  OA  induction,  cartilage  damage  in  the  lateral  joint  compartment  after
multiple PRPr injections was not different from the healthy knees. The severity of the cartilage
damage,  however,  was significantly  increased in  the lateral  compartment  of the CIOA joints
treated with saline. The mild cartilage damage we observed in our study made it difficult to detect
differences between PRPr and saline groups. The absence of a difference between PRPr treated
CIOA mice  and healthy  mice  could  be  an  indication  of  a  chondroprotective  effect  of  PRPr
injections.  No  correlation  between  pain  and  cartilage  damage  at  any  time  point  was  found,
confirming previous findings in the field.32
We used a commercially available human derived PRP, which was pooled from 5 healthy
human donors. Pooling PRP donors can reduce the inter donor variability described previously.30,
56 This PRP is poor in leucocytes and in this study was activated prior to injection in mice. In
contrast,  others inject non-activated PRP and rely on activation  in vivo.4,  8,  12,  41 We choose to
activate the PRP product prior to injection because firstly, it is hard to control the activation of
PRP in vivo, and thus hard to draw conclusions about the working mechanism of PRP without
knowing the level of activation.9 Some of the disappointing results from other studies might be
attributed to less than optimal activation. Secondly,  activating PRP with CaCl2 leads to higher
levels of PDGFβ) and platelet-derived growth factor (PDGF),-AA and BB than other activation methods such as freeze-thaw.46 Thirdly, the
activation of PRP results  in the formation of a  so-called  cloth,  which catches  any remaining
erythrocytes and leucocytes, making the end product low in cells and high in growth factors.
Although possible positive effects of a PRP product rich in leucocytes is still being debated2, a
product depleted from allogenic or in this case xenogeneic cells will cause less immunoreaction.
Lastly,  by having a PRP product low in leucocytes and short storage before activation, we can
reduce the catabolic  factors  in PRP or PRPr.50 Since leucocytes  are  the main contributors  to
TNFβ) and platelet-derived growth factor (PDGF),α) of 0.05, our sample levels in PRP - but also to levels of interleukins 6 and 8 - these levels might increase
further  in  the  period  during  which  leucocyte-rich  PRP is  stored.10,  23 Although  the  working
mechanism of PRP is not fully understood, the current knowledge about its active components is
improving. This will likely help the PRPr product to be optimized by filtering out components,
such as TNFβ) and platelet-derived growth factor (PDGF),α) of 0.05, our sample and vascular endothelial growth factor (VEGFβ) and platelet-derived growth factor (PDGF),), or increasing the concentrations of
other components such as PDGFβ) and platelet-derived growth factor (PDGF),. Others have reported that freeze drying of PRP into a powder
increases its efficacy. Fβ) and platelet-derived growth factor (PDGF),reeze drying could also prolong the lifetime of the PRP product, making it
an  off-the-shelf  product  with  a  longer  lifetime.21,  36 We could  therefore  reduce  the  levels  of
catabolic  factors  in  PRPr by selecting  a  PRP product  low in  leucocytes  and minimizing the
duration  of  storage  before activation.50 Nevertheless,  clinical  studies  most  regularly  use  non-
activated PRP, making our results not fully comparable or immediately clinically translatable.  
Here we have demonstrated  in an OA model that multiple PRPr injections reduce pain
and synovial membrane thickness, and that PRPr appears to modulate the phenotype of synovial
macrophages.  We  believe  that  PRPr  injections  are  a  more  potent  therapy  for  early  stage
intervention after trauma and early OA, rather than a treatment for end-stage OA. The latter is
confirmed in a few clinical trials, where PRP injections did not affect patients with end-stage
OA.18 This knowledge can be used in future experiments to determine the best time point for
intra-articular  PRP  injections  after  trauma,  and  to  further  evaluate  and  confirm  the
chondroprotective effects of PRP in the long term. Together with improvements of the PRP or
PRPr product itself, this could help to make PRP a suitable treatment shorty after joint trauma or
for patients with low grade OA, both for pain relief and the inhibition of OA pathophysiology. 
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